Financials
Financial year 2025
Worth noting
- More debts than assets in the latest financial year.
- A loss two years in a row.
- Little cash and receivables against the short-term debts.
Revenue
€ 8.8 million
▼ 22% vs 2024
Profit
Caution€ -4.3 million
▲ 36% vs 2024
Debts
High€ 15.9 million
▲ 8% vs 2024
ETHERNA IMMUNOTHERAPIES from Niel, company number BE0502703389, closed financial year 2025 with a result of € -4.3 million after tax. For that financial year ETHERNA IMMUNOTHERAPIES recorded revenue of € 8.8 million and equity of € -3.9 million. Compared with financial year 2024, the result moved from € -6.6 million to € -4.3 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 29, 2026.
What happened at ETHERNA IMMUNOTHERAPIES?
What happened at ETHERNA IMMUNOTHERAPIES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Inphacon BV stepped down as director. NBB
- 21-23 Newell Road LLC stepped down as director. NBB
- Antonin Rollet De Fougerolles stepped down as director. NBB
- Biotech Fonds Vlaanderen BV stepped down as director. NBB
- John De Koning stepped down as director. NBB
- Marinus Emmanuel Dekkers stepped down as director. NBB
- Kenneth Chien Randall stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 4.3 million. Source: NBB ↗
In short
From € 17.1 million loss in 2021 to € 4.3 million loss in 2025.
On average € 70,300 of value added per employee in 2021.
Pays suppliers within 144 days on average.
A new publication or filing at ETHERNA IMMUNOTHERAPIES? We notify you, reason included.
Follow ETHERNA IMMUNOTHERAPIESNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 100% of eTheRNA Asia Limited, 100% of Administratiekantoor eTheRNA Immunotherapies, 100% of Etherna Inc. and 0% of Nanjing Aurorna Biotechnology Company Limited itself.
Directors
According to the 2025 annual accounts
Director · represented by Kenneth Wils
Also active at: ViroVet, Flamingo Therapeutics
since 2022 · until 2028
John De Koning
Director
since 2022 · until 2028
Marinus Emmanuel Dekkers
Director
since 2022 · until 2028
Director · represented by Bernard Sagaert
since 2024 · until 2030
Kenneth Chien Randall
Director
since 2022 · until 2028
21-23 Newell Road LLC
Director · represented by Philip Chase
since 2023 · until 2029
Antonin Rollet De Fougerolles
Chairman of the board
since 2024 · until 2028
Establishments
Establishment units
Physical locations of this company
Galileilaan 19
2845 Niel
Frieda Saeysstraat 1B
9052 Gent
Active since 23 January 2013
Galileilaan 21 box Unit 2
2845 Niel
Active since 25 April 2019
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
Details
- Company number
- 0502.703.389
- VAT number
- BE 0502.703.389
- Registered office
- Galileilaan 19, 2845 Niel
- Names & denominations
- ETHERNA IMMUNOTHERAPIES
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 21 January 2013
- Peppol
- Active · Active since 24 Nov 2023
- Contact
- etherna.be info@etherna.be
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op biotechnologisch gebied
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Vervaardiging van overige farmaceutische producten
Vervaardiging van farmaceutische grondstoffen
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering